What Ilomedin Treats: Main Uses and Benefits

Ilomedin, which contains the active substance iloprost, is generally used for managing conditions characterized by periods of heightened symptoms related to reduced blood flow in the vascular system. Its primary therapeutic domains involve addressing symptoms linked to organ-specific functional stress.

The substance is applied in addressing conditions associated with acute or disruptive episodes, specifically for the symptomatic management of three main areas: severe peripheral arterial occlusive disease (in stages with ulcers or rest pain), thromboangiitis obliterans, and severe Raynaud's phenomenon. Additionally, the inhaled form may be part of symptomatic management for pulmonary arterial hypertension (PAH), where it contributes to improved comfort during periods of heightened symptoms.

The medicine supports the patient during difficult episodes by easing distress. This means that Ilomedin assists with maintaining functional stability by addressing localized or systemic imbalance. “provides support that helps ease the overall symptom burden.”

Quick Fact: Relief for Symptoms related to physical discomfort

Ilomedin (Iloprost) is officially restricted to the adult population and is defined by a rigorous set of absolute contraindications based on regulatory labeling.

Populations Who Must Not Use Ilomedin (Contraindications)

The medicine must not be used in populations with conditions that pose an unacceptably high risk due to the drug’s effects. Use is formally contraindicated for:

• Pregnancy and Lactation: The medicine is strictly prohibited during pregnancy and breastfeeding.
• Severe Cardiac Instability: Contraindicated in patients with recent myocardial infarction (within six months), unstable angina, severe arrhythmias, or decompensated cardiac failure (NYHA Class II–IV).
• Hemorrhagic Risk: Contraindicated in conditions that increase bleeding risk, such as active peptic ulcers, recent trauma, or intracranial haemorrhage.
• Hypotension: Treatment should not be initiated if systolic blood pressure is less than 85 mmHg.

Use Limitations and Restrictions

Eligibility is restricted for specific populations based on organ function, requiring mandatory caution and dose adjustment:

• Hepatic/Renal Impairment: Patients with severe hepatic impairment or renal failure requiring dialysis must use a reduced initial dose due to altered drug elimination.
• Pediatric Use: Safety and efficacy have not been established in children and adolescents (under 18 years) due to insufficient clinical data.

Interactions with other medicines and products

The official regulatory profile for Iloprost (the active substance in Ilomedin) is defined by its potential to interact with other medicines through two primary pathways: additive pharmacodynamic effects and altered drug clearance.

Pharmacodynamic Interactions Co-administration with antihypertensive agents and other vasodilators may lead to an additive pharmacodynamic effect, officially described as the potential to increase the hypotensive effect. Similarly, combining Iloprost with anticoagulants (such as coumarin-type medicines) or platelet inhibitors (including non-steroidal anti-inflammatory drugs) carries the potential for increased risk of bleeding due to additive inhibition of platelet function. The drug does not affect the pharmacokinetics of co-administered medicines like Digoxin or Acetylsalicylic acid.

Pharmacokinetic and Clearance Notes Iloprost's biotransformation is primarily by beta-oxidation, meaning Cytochrome P450-dependent metabolism plays only a minor role; therefore, clinically relevant CYP-mediated interactions are not anticipated. However, the elimination of Iloprost is reduced in patients with hepatic dysfunction and those with renal failure requiring dialysis. This reduction in clearance creates a risk of undesired accumulation over the day. To manage this specific population-dependent pharmacokinetic constraint, regulatory documents require that administration in these patient groups use adjusted dosing intervals (e.g., 3–4 hours separation). Additionally, the final ready-to-use infusion solution must not be admixed with other parenteral medications.

Ilomedin, a synthetic prostacyclin analogue (iloprost), functions as an agonist primarily targeting the prostacyclin receptor (IP receptor), a G-protein-coupled receptor, expressed on the surface of vascular smooth muscle cells and platelets. Binding to the IP receptor activates the associated G-protein, stimulating the enzyme adenylate cyclase. This interaction catalyzes the conversion of intracellular adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP), resulting in elevated intracellular cAMP levels. The subsequent rise in cAMP activates protein kinase A (PKA).

In vascular smooth muscle cells, PKA activation leads to the phosphorylation and inhibition of myosin light chain kinase (MLCK). This prevents the phosphorylation of myosin light chains, modulating the contractile state and inducing vasodilation in both pulmonary and systemic vascular beds.

In platelets, PKA-mediated phosphorylation affects proteins such as vasodilator-stimulated phosphoprotein (VASP), resulting in the inhibition of platelet aggregation by preventing the activation of the glycoprotein IIb/IIIa receptors and reducing the release of pro-aggregatory factors. The net physiological consequences are decreased vascular resistance and antiplatelet activity.

How to Use Ilomedin — Official Administration Guidelines

Ilomedin (iloprost) is administered strictly as a slow intravenous (IV) infusion and must be performed only in a hospital or specialized clinical setting with appropriate facilities for monitoring. Treatment is typically delivered once daily for a course that may last up to four consecutive weeks.

---

Administration Scope

Feature	Official Instruction Summary
Route & Frequency	Intravenous infusion, administered daily over a 6-hour period
Dosing Schedule	Dosage is weight-based (ng/kg/min) and adjusted according to individual tolerability; the maximum dose is 2.0 ng/kg/min
Monitoring	Blood pressure and heart rate must be measured at the start of the infusion and with every dose increase to ensure tolerability

---

Preparation and Procedural Steps

1. Preparation: The solution must be prepared freshly each day immediately before use.
2. Dilution: The concentrated solution must be diluted using only 0.9% Sodium Chloride or 5% Glucose solution; no other diluents or medications are permitted.
3. Titration: The initial infusion rate begins low (e.g., 0.5, mathrmng/kg/min) and is then increased stepwise every 30 minutes during the first 2-3 days until the maximum tolerated dose is established. The subsequent daily infusions use this maximum tolerated dose.

---

The Official Use Protocol

These instructions define a controlled, standardized process where the drug is administered as a daily, time-restricted IV infusion. The mandatory initial titration phase structures the use by establishing a personalized, weight-adjusted infusion rate that minimizes the risk of intolerance. This procedural requirement for constant monitoring and specialized preparation ensures the standardized and controlled delivery of the drug.

Research Evidence / Overview of Studies for Ilomedin

This overview summarizes the structure of the clinical evaluation for the active substance iloprost (the active ingredient in Ilomedin) as documented in scientific literature. This section describes the research framework and research context in a neutral way and does not constitute medical advice or predict individual patient outcomes.

---

Evidence in Peripheral Vascular Conditions

Research has examined iloprost in controlled, randomized trials (RCTs) for severe Peripheral Arterial Occlusive Disease (PAOD) with tissue damage. The primary goal of these studies was to look at major outcomes related to systemic or functional imbalance, such as whether patients required a major amputation, and to monitor the measurement of outcomes related to physical discomfort (like rest pain). Long-term observational studies data show patterns related to major clinical events over several years.

For Thromboangiitis Obliterans (TAO) and severe Raynaud's Phenomenon, research explored short-term infusions in randomized trials to examine changes in ulcer healing and outcomes related to physical discomfort. Findings were mixed across different formulations, and the sample sizes were modest for TAO trials. Separately, the inhaled formulation of iloprost was studied for Pulmonary Arterial Hypertension (PAH), where trials examined outcomes reflecting daily functioning or activity level.

---

Research Landscape and Gaps

While the available research is documented, initial RCTs often have follow-up durations that were limited to a few months, meaning long-term effects are not fully established. Research on the optimal number and frequency of repeat infusions over many years is not standardized across the research base.

The majority of research was studied for adults, and data for certain groups remain insufficient. For instance, specific, definitive research on iloprost in pediatric populations or for use during pregnancy is largely absent from the pivotal randomized trials. Furthermore, comparative evidence is lacking against all modern-day standard treatments for certain indications.

Common questions about Ilomedin (FAQ)

---

Q: Are there any foods or drinks I should avoid while being treated with Ilomedin?

According to official regulatory documents, there are no specific foods or non-alcoholic drinks that must be avoided while receiving Ilomedin. It is important that the care team is informed about your diet and any supplements being taken.

---

Q: Will Ilomedin affect my ability to drive or operate machinery?

Ilomedin may temporarily affect the ability to drive or use machines. Because the medicine can cause side effects like dizziness or low blood pressure, patients who experience these effects are advised to avoid driving or operating complex machinery during treatment.

---

Q: Are there known interactions between Ilomedin and herbal supplements?

Official regulatory documents only list known interactions with specific prescription and over-the-counter medicines, and do not explicitly address herbal supplements. It is generally required that all supplements are disclosed to the care team before and during treatment.

---

Q: Why is Ilomedin used to treat Buerger's disease?

Ilomedin is officially indicated for treating severe circulatory disorders, including a condition known as Thromboangiitis Obliterans (TAO), which is also called Buerger's disease. It is used in cases of severe blockage and tissue damage that is not due to generalized vascular hardening.

---

Q: Can Ilomedin be given to children?

The official product information states that the safety and effectiveness of Ilomedin have not been established for children and adolescents under 18 years of age. This is due to a lack of sufficient clinical data in this patient population.

---

Q: Can I take my regular vitamins while getting Ilomedin?

While the medicine's official label does not list any specific interactions with vitamins, it is required that all medications and supplements are disclosed to the treating physician. This ensures the care team can monitor for any potential effects.

---

Q: Is Ilomedin similar to prostacyclin or prostaglandins?

Yes. Ilomedin contains the active substance iloprost, which is classified as a synthetic analogue of naturally occurring prostacyclin ( PGI2). This structure is responsible for its dual physiological action as a vasodilator and platelet aggregation inhibitor.

---

Q: How is Ilomedin stored before it is administered?

The unopened concentrated solution must be stored below 25 °C and must not be frozen. The final ready-to-use solution for infusion must be freshly prepared each day immediately before administration.

---

Q: Can a patient stop Ilomedin treatment suddenly?

The medicine is not typically stopped suddenly. Cessation or reduction of the infusion must only be done under professional medical guidance. If adverse effects occur, official instructions recommend that the infusion rate is gradually reduced in a stepwise manner.

---

Q: Does Ilomedin cause fatigue or tiredness?

Fatigue or generalized tiredness is not listed among the very common or common side effects in the official product information. The most frequently reported side effects relate to its action on blood pressure and blood vessels, such as headache and flushing.

---

Q: Can I drink alcohol during the treatment period with Ilomedin?

Ilomedin contains a small amount of ethanol (alcohol) as an inactive ingredient. Any consumption of additional alcoholic drinks during treatment should be discussed with a healthcare professional.

---

Q: What happens to the medicine in my body after the infusion is finished?

The active substance is eliminated from the body very quickly once the infusion is complete. Following the end of the IV, the concentration of the medicine in the blood drops rapidly, having a very short terminal half-life.

---

Q: Does Ilomedin reduce the need for amputations in severe cases?

In clinical trials for severe Peripheral Arterial Occlusive Disease (PAOD) with tissue damage, the medicine was evaluated based on the goal of reducing the risk of major amputation. This was one of the key indicators of efficacy reviewed in the research.

---

Q: Is Ilomedin a pain reliever or does it treat the underlying condition?

Ilomedin is primarily used to treat the underlying severe chronic arterial insufficiency by improving blood flow. Additionally, official indications include its use for the relief of severe rest pain associated with these circulatory conditions.

---

Q: Can patients who have had a stroke use Ilomedin?

The medicine is contraindicated in patients with conditions that carry an increased risk of bleeding, such as a recent intracranial haemorrhage. Any history of stroke or bleeding risk requires discussion with the treating physician before the medicine is started.

Storage and Disposal Conditions for Ilomedin

Ilomedin (iloprost concentrate for solution for infusion) must be handled and stored according to specific regulatory requirements to ensure its stability and safe use.

---

Storage Requirements

Condition	Requirement
Temperature	Store the unopened concentrate below 25°C and do not freeze.
Packaging	Must be kept in the original container.
Stability	The diluted infusion solution must be prepared freshly each day.
Child Safety	Keep out of the sight and reach of children.

---

Handling and Disposal

The product does not require protection from light for storage. Handling requires caution to avoid contact with the skin; wash immediately with water or saline if contact occurs. All unused medicinal product and waste material must be disposed of in accordance with local requirements for pharmaceutical waste.